Repligen gets fast tracked for spinal muscular atrophy

Waltham, MA-based biotech Repligen has received FDA fast-track designation for its spinal muscular atrophy treatment, RG3039. The drug also received orphan drug status from the EMA. Repligen is preparing for its first Phase I trial of the drug. Repligen release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.